Polymorphic transformation of indomethacin in precirol solid dispersion system
Tóm tắt
The polymorphic transformation of indomethacin (IMC) in the presence of Precirol during heating was investigated by differential scanning calorimetry (DSC), infrared (IR) spectroscopy, microscopic Fourier transform infrared (FT-IR)/DSC system, and powder X-ray diffractometry with heating. The results indicate that in the presence of Precirol the original γ form of IMC was first transformed to a transition state, and then to a new polymorph by heating or exposure to IR radiation. The transition state of the melted sample gave three endothermic peaks, at 34, 48 and 127°C, and one exothermic peak, at 54°C. The stable melted sample exhibited two endothermic peaks, at 58 and 127°C, which were due to the fusion of Precirol and the new polymorph of IMC, respectively. This new polymorph of IMC also exhibited two specific IR absorption peaks, at 1693 and 1675 cm−1. Microscopic FT-IR/DSC was used to examine the correlation between the structural transformation and its thermal response, and demonstrated the existence of the transition state of the melted sample. X-ray diffractometry with heating confirmed the appearance of the new polymorph of IMC in the presence of Precirol after heating.
Tài liệu tham khảo
W. L. Chiou and S. Riegelmann, J. Pharm. Sci., 60 (1971) 1281.
J. Kreuter, Topics in Pharmaceutical Sciences 1983, D. D. Breimer; P. P. Speiser (Eds.), Elsevier Sci. Publ., 1983, pp. 359–370.
D. W. Bloch and P. P. Speiser, Pharm. Acta Helv., 62 (1987) 23.
H. Yuasa, T. Ozeki, Y. Kayeya, K. Oishi and T. Oyake, Chem. Pharm. Bull., 39 (1991) 465.
N. Onishi, T. Yokoyama, T. Umeda, T. Kiyohara, T. Kuroda, Y. Kita and K. Kuroda, Chem. Pharm. Bull., 34 (1986) 2999.
A. Hasegawa, R. Rawamura, H. Nakagawa and I. Sugimoto, Chem. Pharm. Bull., 34 (1986) 2183.
J. E. Hilton and M. P. Summers, Int. J. Pharm., 31 (1986) 157.
J. L. Ford and M. H. Rubinstein, Pharm. Acta Helv., 53 (1978) 93.
J. E. Hilton and M. P. Summers, Int. J. Pharm., 33 (1986) 219.
H. Imaizumi, N. Nambu and T. Nagai, Chem. Pharm. Bull., 31 (1983) 2510.
M. Fujii, H. Terai, T. Mori, Y. Sawada and M. Matsumoto, Chem. Pharm. Bull., 36 (1988) 2186.
K. Takayama, N. Nambu and T. Nagai, Chem. Pharm. Bull., 30 (1982) 673.
S. Shiraishi, T. Imai, D. Iwaoka and M. Otagiri, J. Pharm. Pharmacol., 43 (1991) 615.
H. Imaizumi, N. Nambu and T. Nagai, Chem. Pharm. Bull., 28 (1980) 2565.
J. L. Ford and M. H. Rubinstein, Pharm. Acta Helv., 54 (1979) 353.
N. Kaneniwa, M. Otsuka and T. Hayashi, Chem. Pharm. Bull., 33 (1985) 3447.
D. C. Monkhouse and J. L. Lach, J. Pharm. Sci., 61 (1972) 1435
S. Y. Lin, J. Pharm. Sci., 81 (1992) 572.
S. Y. Lin and R. I. Perng, STP Pharma. Sci., 3 (1993) 465.
R. Bodmeier, O. Paeratakul, H. Chen and W. Zhang, Drug Devel. Indus. Pharm., 16 (1990) 1505.
S. Malamataris, A. Panagopoulou and P. Hatzipantou, Drug Devel. Indus. Pharm., 17 (1991) 1765.
H. Yamamoto, Chem. Pharm. Bull., 16 (1968) 17.
L. Borka, Acta Pharm. Suec., 11 (1974) 295.
S. Y. Tsai, S. C. Kuo and S. Y. Lin, J. Pharm. Sci., 82 (1993) 1250.
T. Imai, S. Shiraishi, H. Saito and M. Otagiri, Int. J. Pharm., 67 (1991) 11.